Abstract: The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
April 9, 2019
Assignee:
uniQure IP B.V.
Inventors:
Wilhelmus Theodorus Johannes Maria Christiaan Hermens, James Patrick Smith
Abstract: The invention relates to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein the adenoviruses are generated in a production cell by: (a) expressing an adenoviral pIX polypeptide from a nucleic acid sequence encoding adenoviral pIX polypeptide under the control of at least a minimal endogenous pIX promoter and a heterologous promoter; and (b) expressing the elements necessary for the production and assembly of the adenoviruses, thereby increasing the yield of adenoviruses generated in the production cell in comparison to the yield in the absence of nucleic acid sequence encoding the adenoviral pIX polypeptide. Further, the invention relates to a method for constructing an adenovirus library, a production cell, and the use of an adenoviral pIX polypeptide for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region.
Abstract: This invention provides an improved process for manufacturing a Rabies monoclonal antibody (HuMab 17C7) that results in low osmolality, minimum secondary metabolites like ammonia and lactate, enhanced cell growth and productivity, minimum aggregation or degradation of monoclonal antibody during purification, thereby improving potency of monoclonal antibody (HuMab 17C7) as compared to human rabies immunoglobulin (hRIG).
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
March 19, 2019
Assignee:
Serum Institute of India Private Limited
Abstract: A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles.
Type:
Grant
Filed:
March 31, 2011
Date of Patent:
February 19, 2019
Assignee:
Stabilitech Biopharma Ltd
Inventors:
Jeffrey Drew, David Woodward, John Bainbridge, Amanda Corteyn
Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.
Type:
Grant
Filed:
August 22, 2012
Date of Patent:
February 19, 2019
Assignee:
NanoBio Corporation
Inventors:
Ali I. Fattom, Jakub Simon, James R. Baker, Jr., Tarek Hamouda, Vira Bitko
Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
Type:
Grant
Filed:
March 29, 2016
Date of Patent:
February 19, 2019
Assignees:
Emory University, The University of Chicago
Inventors:
Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
Abstract: The present disclosure provides compositions including recombinant K1-5 bacteriophages, methods for making the same, and uses thereof. The recombinant K1-5 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
February 12, 2019
Assignee:
The Charles Stark Draper Laboratory, Inc.
Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.
Abstract: The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4 linked to the N-terminal of HBsAg.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
January 29, 2019
Assignee:
International Centre for Genetic Engineering and Biotechnology
Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
January 22, 2019
Assignee:
Genentech, Inc.
Inventors:
Masaru Ken Shiratori, Robert David Kiss, Hardayal Prashad, Raquel Iverson, Justin Bourret, Michael Kim, Salim Charaniya
Abstract: A recombinant baculovirus displaying on its envelop a fusion protein is disclosed. The fusion protein comprises a heterologous antigen, and a C-terminal region of baculovirus envelope GP64 protein, which has at least 100 amino acid residues in length and lacks a B12D5 binding epitope located within the central basic region of the GP64 protein. The genome of the recombinant baculovirus comprises a transgene encoding a fusion protein that comprises a signal peptide, the heterologous antigen, and the C-terminal region of the baculovirus envelope GP64 protein, in which the antigen is located between the signal peptide and the C-terminal region of the GP64 protein. Methods for eliciting an antigen-specific immunogenic response in a subject in need thereof are also disclosed.
Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
December 25, 2018
Assignee:
Variation Biotechnologies Inc.
Inventors:
David E. Anderson, Jasminka Bozic, Barthelemy Ontsouka
Abstract: The invention is to provide a method and kit based on recombinase polymerase amplification (RPA) and lateral flow dipstick (LFD) for detection of caprine arthritis-encephalitis virus (CAEV) infection. The method and kit are suitable for both laboratory and field application, and are specific and sensitive for detecting CAEV proviral DNA in goats in a fast manner. The method and lit of the invention are also applicable for on-site utilization at farms and should be useful in both eradication programs and epidemiological studies.
Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.
Type:
Grant
Filed:
October 28, 2013
Date of Patent:
October 30, 2018
Assignee:
The Regents of the University of California
Inventors:
Andrew C. Kummel, Sarah L. Blair, Tony R. Reid, William C. Trogler, Farah Hedjran, Natalie Mendez, Vanessa Herrera
Abstract: The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
October 23, 2018
Assignee:
HVIDOVRE HOSPITAL
Inventors:
Yiping Li, Santseharay Ramirez Almeida, Daryl Grant Humes, Judith M. Gottwein, Jens Bukh
Abstract: For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.
Abstract: The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) of genotype 2b that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs, which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.
Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
October 16, 2018
Assignees:
Hvidovre Hospital, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh